Why is Ambu stock surging today?

Ambu A/S stock surged 6.7% today after the Danish medical device maker published its annual report for fiscal 2025/26, revealing fourth-quarter revenue of DKK 1,700 million — a gain of 13.9% on an organic basis and 16% on a reported basis compared to the same period a year earlier.

The quarter’s EBIT came in at DKK 293 million, representing a 17.2% margin, a sharp improvement from the 10% margin recorded in the prior-year period, reflecting strong operating leverage and positive tariff reclaim effects.

The standout performer was the Endoscopy Solutions segment, which posted 21.2% organic growth in the quarter, with Respiratory and Urology/ENT/GI each also delivering more than 21% organic growth.

Compounding the positive earnings surprise, management announced a DKK 400 million share buyback program alongside a proposed DKK 151 million dividend for fiscal 2026/27, and guided for full-year organic revenue growth of 9.5% to 11.5% with an EBIT margin of 13% to 15% — projections that signal sustained momentum.

CEO Britt Meelby Jensen stated: "We ended the year with strong momentum, delivering 13.9% organic revenue growth in Q4, driven by 21.2% organic growth in Endoscopy Solutions."

The broader market environment provided a modestly supportive backdrop, with the OMX Copenhagen 25 Index — the primary benchmark for Danish blue-chip equities and the index of which Ambu is a component — edging up 0.3% on the day.

U.S. markets offered a mixed picture, with the S&P 500 essentially flat and the Nasdaq in slight negative territory, underscoring that today’s move in Ambu was almost entirely a function of company-specific catalysts rather than any macro or sector-wide tailwind.

Taken together, the combination of a materially strong quarterly result, a significant beat on profitability metrics, an optimistic multi-year growth outlook anchored by the high-growth Endoscopy Solutions franchise, and a generous capital return announcement created a powerful confluence of positive signals that pushed the shares to a new 52-week high of 92 DKK intraday — a level not seen since the stock’s 52-week peak of 92.2 DKK.